Literature DB >> 9142052

Role of serotonin in nephrotoxic serum nephritis in WKY rats.

H Kanai1, K Hiromura, T Kuroiwa, A Maezawa, S Yano, T Naruse.   

Abstract

Our objective was to determine whether serotonin is involved in inducing nephrotoxic serum nephritis in WKY rats. After injection of antiglomerular basement membrane antiserum, urinary protein excretion was significantly decreased in rats treated with the serotonin receptor antagonist, MCI-9042, and in rats treated with p-chlorophenylalanine. Similarly, severe necrotizing lesions and crescent formation were inhibited in a dose-dependent manner by treatment with MCI-9042 and p-chlorophenylalanine. The number of intraglomerular ED-1-positive cells was increased on day 3 and thereafter in the placebo group. A significant increase in the number of crescent lesions was observed in the placebo group on day 7 and thereafter. Neither adenosine diphosphate- nor collagen-induced platelet aggregations were inhibited in platelet-rich plasma from rats treated with MCI-9042. No significant differences were observed in the production of circulating antibody and antibody deposition in rat glomeruli among the study groups. These results indicate that pathologic changes and urinary protein excretion are closely related to the presence of serotonin in nephrotoxic serum nephritis of WKY rats. Thus serotonin may play a key role in the glomerular injury in this model. Studies on the mode of action of MCI-9042 on platelet aggregation in vivo indicate that the antiplatelet effect of this drug did not contribute to the inhibition of renal injury in this experimental model. This study suggests that serotonin participates in macrophage-mediated immune injury in nephrotoxic serum nephritis of WKY rats.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142052     DOI: 10.1016/s0022-2143(97)90010-x

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  3 in total

1.  The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial.

Authors:  Kyungil Park; Woo-Young Chung; Jae-Bin Seo; Sang-Hyun Kim; Joo-Hee Zo; Myung-A Kim; Young-Bae Park
Journal:  Trials       Date:  2010-12-20       Impact factor: 2.279

Review 2.  Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade.

Authors:  Maria Vanessa Perez-Gomez; Maria Dolores Sanchez-Niño; Ana Belen Sanz; Catalina Martín-Cleary; Marta Ruiz-Ortega; Jesus Egido; Juan F Navarro-González; Alberto Ortiz; Beatriz Fernandez-Fernandez
Journal:  J Clin Med       Date:  2015-06-18       Impact factor: 4.241

3.  The Prevention of Contrast Induced Nephropathy by Sarpogrelate: a Prospective Randomized Controlled Clinical Trial.

Authors:  You Jeong Ki; Sun A Kwon; Hack Lyoung Kim; Jae Bin Seo; Woo Young Chung
Journal:  J Korean Med Sci       Date:  2019-10-21       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.